MedTrace Logo

Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections

NCT03651882 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2023-05-24

No results posted yet for this study

Summary

Objective is to proof non-inferiority of intramyometrial and intravenous oxytocin application compared to intravenous carbetocin for prevention of postpartum hemorrhage in planned, uncomplicated cesarean deliveries.

Conditions

  • Postpartum Hemorrhage

Interventions

DRUG

Oxytocin

Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.

DRUG

Carbetocin

Carbetocin is given 0.1mg intravenously as a bolus after delivery.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Christian Haslinger, M.D. · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-07
Primary Completion
2022-01-10
Completion
2022-01-10

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03651882 on ClinicalTrials.gov